Phase 3 Stroke Trial, Recruiting NCT06301412 Sponsor: University of Freiburg Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06301412
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who had little to no disability before their stroke (scoring 0–2 on a standard pre-stroke disability scale)
  • People currently experiencing an acute ischemic stroke (a stroke caused by a blockage) that is considered moderate to severe based on a standard neurological assessment
  • People whose stroke is caused by a blockage in a specific artery in the brain (the middle cerebral artery or internal carotid artery), confirmed by a CT or MRI scan, for which a procedure to remove the blockage is planned
  • People treated within 24 hours of when they were last seen well — within 6 hours, a standard brain scan showing enough healthy brain tissue is required; between 6 and 24 hours (or if the time of stroke is unknown), specific advanced imaging must show a significant area of brain that is at risk but not yet damaged, meeting set size and ratio thresholds
  • People who have or have not received a clot-dissolving drug (rtPA) given through a vein

Who may not be able to join:

  • People with a nasal blockage that would prevent a nasal tube from being fully inserted
  • People with a known serious bleeding disorder, or whose blood test results show very poor clotting (confirm with trial site for specific values)
  • People who have had a brain injury or brain surgery/procedure within the last 3 months
  • People with a serious active infection
  • Women who are pregnant (women of childbearing age with a negative pregnancy test may still be considered eligible)
  • People with a known condition causing inflammation of the blood vessels in the brain (cerebral vasculitis)
  • People whose brain scan shows active bleeding (note: certain small, pre-existing spots seen on MRI may still be permitted — confirm with trial site)
  • People with a known life expectancy of less than 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Juergen Bardutzky, Prof., University of Freiburg, Department of Neurology, Germany

Phone: +49-15237729739

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Freiburg
Registry
ClinicalTrials.gov
Start date
7 July 2024
Est. completion
18 March 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

functional outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov